• 中国核心期刊(遴选)数据库收录期刊
  • 中文科技期刊数据库收录期刊
  • 中国期刊全文数据库收录期刊
  • 中国学术期刊综合评价数据库统计源期刊等

快速检索引用检索图表检索高级检索

中国医药导刊 ›› 2022, Vol. 24 ›› Issue (10): 988-992.

• 论著 • 上一篇    下一篇

阿法骨化醇联合降钙素治疗骨质疏松症患者的有效性

柳玉兵, 王平*   

  1. 陕西省西安高新医院, 陕西 西安 710016
  • 收稿日期:2022-11-01 出版日期:2022-10-28 发布日期:2022-10-28

Effectiveness of Alfacalcidol Combined with Calcitonin in the Treatment of Osteoporosis

  1. Shaanxi Province Xi′an Gightech Hospital, Shaanxi Xi′an 710016,China
  • Received:2022-11-01 Online:2022-10-28 Published:2022-10-28

摘要: 目的:探讨阿法骨化醇联合降钙素治疗骨质疏松症患者的有效性及对骨密度水平的影响。方法:选取我院2020年6月至2021年7月收治的骨质疏松患者190例作为研究对象,采用随机数字表法将所有患者分为对照组(n=95)和观察组(n=95)。两组患者均常规补充钙剂,对照组患者给予鲑鱼降钙素注射液肌内注射治疗,观察组患者在对照组治疗基础上,鲑鱼降钙素注射液肌内注射联合阿法骨化醇胶囊口服治疗。两组患者均连续用药3个月。比较两组患者的临床疗效;检测治疗前后股骨颈、腰椎1~4骨密度;检测两组患者骨代谢及炎性水平变化;统计治疗期间不良反应,观察两组患者自发性痛、翻身痛、后伸前屈痛、负重痛的疼痛评分变化。结果:观察组患者治疗总有效率为91.58%,高于对照组的71.58%(P<0.05);治疗后,两组患者自发性痛、翻身痛、后伸前屈痛、负重痛VAS评分及血清Ⅰ型前胶原氨基端前肽(PINP)、骨钙素(BGP)、白细胞介素6(IL6)、肿瘤坏死因子α(TNFα)水平均低于治疗前,且观察组降低程度较对照组更为明显(P<0.05);两组患者股骨颈、腰椎14骨密度及血清BGP水平均升高,且观察组升高程度较对照组更为明显(P<0.05);两组患者治疗期间不良反应发生率差异无统计学意义(5.26% vs 4.21%,χ2=0.130,P=0.718)。结论:阿法骨化醇联合降钙素治疗骨质疏松症患者,可降低骨质疏松症患者疼痛程度,增加患者骨密度水平,调节骨代谢,降低机体炎性反应,临床疗效优于降钙素单用。

关键词: font-size:medium, ">骨质疏松症;阿法骨化醇;降钙素;骨密度

Abstract: Objective:To investigate the effectiveness of alfacalcidol combined with calcitonin in the treatment of osteoporosis patients and its effect on level of bone mineral density. Methods: A total of 190 patients with osteoporosis treated in our hospital from June 2020 to July 2021 were selected, and the patients were randomly divided into the control group (n=95) and the observation group (n=95) according to the random number table method. Calcium supplements were routinely given in the two groups. Patients in the control group were given salmon calcitonin injection intramuscularly,and patients in the observation group were given alfacalcidol capsules on the basis of the treatment of the control group. Both groups were treated continuously for 3 months. The clinical efficacy of the two groups was compared. The bone density of femoral neck and lumbar vertebrae 1 -4 before and after the treatment were measured. The changes in pain scores of spontaneous pain, turning pain, flexion and extension pain, and weightbearing pain in both groups were observed, and bone metabolism and serum inflammation level changes in the two groups were detected. The adverse reactions occurred during treatment were counted. Results: The total effective rate of the observation group was 91.58%, which was higher than that of the control group(71.58%) (P<0.05). After treatment, the spontaneous pain, turning pain, flexion and extension pain, weightbearing pain VAS scores, and serum PINP, BNP, IL6, TNFα levels in the two groups were lower than those before treatment, and the decrease degree of the observation group were greater than those of the control group (P<0.05). The femoral and lumbar vertebral bone density and serum BGP levels of patients in the two groups all increased, and the observation group increased more obviously than the control group (P<0.05). There was no significant difference in the incidence of adverse reactions of the two groups during the treatment (5.26% vs 4.21%, χ2=0.130, P=0.718). Conclusion: Alfacalcifdol combined with calcitonin can reduce the pain of patients with osteoporosis, increase bone mineral density, regulate bone metabolism, and reduce inflammatory reactions. The clinical efficacy is better than that of the calcitonin

Key words: font-size:medium, ">Osteoporosis; Alfacalcidol; Calcitonin; Bone density

中图分类号: